Slayback Pharma
Slayback Pharma is a privately held specialty pharmaceutical company with 50+ medicines across 10 therapeutic areas and a 50+ country footprint, focused on serving overlooked patient populations through practical, administration-friendly formulations and multi-channel global distribution.
- Company typePrivate
- Founded2019
- HeadquartersPrinceton, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What Slayback Pharma does
Slayback Pharma is a specialty pharmaceutical company founded in 2011, headquartered in Princeton, United States, with 101-250 employees. The company develops and commercializes a diversified portfolio of 50+ medicines spanning 10 dosage forms and 10 therapeutic areas, including cardiovascular, central nervous system, oncology, endocrinology, gastrointestinal, hematology, immunology, allergy, anti-infective, and respiratory. Slayback's stated focus is on serving "overlooked patients" — populations underserved by traditional pharmaceutical approaches — through practical, administration-friendly formulations.
The company operates a Next-Gen Commercial Model leveraging data, analytics, and AI-driven digital tools to enhance market reach and stakeholder engagement. Its distribution architecture is multi-channel and global, spanning 50+ countries and incorporating pharmacy distribution, patient-direct programs, and clinical kits for institutional settings. Recent strategic activity includes the FDA approval of an Aprepitant Injectable Emulsion for supportive oncology care (June 2026), new product launches such as Ferabright, Javadin, and Xifyrm, and a partnership with ACA Pharma to expand ferumoxytol-based products into Macau and Greater China.
Slayback has raised approximately $110M in disclosed growth funding from marquee private equity sponsors Kohlberg Kravis Roberts & Co. ($60M, 2017) and Everstone ($50M, 2020). The company remains privately held. Its revenue model is anchored in one-time product sales across its pharmaceutical portfolio, with pricing conducted on a quote basis through pharmacy and institutional channels rather than publicly disclosed list pricing.
Slayback Pharma firmographics
Firmographics- Name
- Slayback Pharma
- Legal name
- Azurity Pharmaceuticals, Inc.
- Website
- https://slayback-pharma.com
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- Slayback Pharma is a privately held specialty pharmaceutical company with 50+ medicines across 10 therapeutic areas and a 50+ country footprint, focused on serving overlooked patient populations through practical, administration-friendly formulations and multi-channel global distribution.
- Ownership category
- akta.pro rank
Slayback Pharma industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Specialty Care Pharmaceuticals (HLAIAAAB)
- akta.pro secondary industries
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA), Infectious Disease Specialty Pharmaceuticals (Non-vaccine) (HLAIACAM)
Keywords
Where Slayback Pharma is headquartered
LocationHeadquarters
- HQ city
- Princeton
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Slayback Pharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Operations, Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Product Sales: Azurity generates revenue through the sale of specialty pharmaceutical products across 10 therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a portfolio of 50+ medicines spanning 10 dosage forms.
Go-to-market motion1 record
Distribution channels4 records
Marketing channels3 records
Slayback Pharma product offering
Product offeringCore offering
Slayback Pharma is a specialty pharmaceutical company that develops, manufactures, and commercializes complex generic and branded prescription medicines across multiple therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a diversified portfolio of 50+ medicines spanning 10 dosage forms, with a focus on overlooked patient populations requiring specialized formulations and administration-friendly treatment options.
Differentiator
Problem solved
Functional benefit
Products and services
- FerabrightTM Ferumoxytol-based pharmaceutical product for iron deficiency treatment, distributed globally through regulatory and distribution partners.
- JavadinTM Cardiovascular pharmaceutical product for patients with cardiac conditions.
- Feraheme Ferumoxytol-based intravenous iron replacement product for treatment of iron deficiency anemia.
- Cardiovascular/Cardiology Portfolio Portfolio of cardiovascular medicines including BiDil, EDARBI, EDARBYCLOR, EPANED, KATERZIA, LANOXIN, QBRELIS, SOTYLIZE, SULAR, WIDAPLIK, and JAVADIN for treatment of cardiovascular conditions.
- CNS/Cerebrovascular Portfolio Central nervous system medicines including ARYNTA, EPRONTIA, EVEKEO, FERABRIGHT, FLEQSUVY, HORIZANT, NYMALIZE, XIFYRM, ZENZEDI, ZONISADE for CNS and cerebrovascular disorders.
- Gastrointestinal Portfolio Gastrointestinal medicines including KONVOMEP, PRILOSEC, SUFLAVE, SUPREP, SUTAB for GI conditions and bowel preparation.
- Oncology Portfolio
Quantifiable outcome
- Millions of people have benefited from Azurity medicines globally
Companies that use Slayback Pharma
Customer profileNamed customers1 record
Segments1 record
Ideal customer profiles1 record
Slayback Pharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Slayback Pharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ACA PharmacoreACA Pharma and Azurity Pharmaceuticals announced regulatory approval of Feraheme and Ferabright in Macau, marking expansion of ferumoxytol-based products across key Asian markets. This partnership advances regulatory pathways and improves patient access throughout Greater China.
Scale indicators4 records
Recent moves5 records
Expansion highlights5 records
Slayback Pharma competitors and assessment
Company assessmentDirect peers
- Azurity Pharmaceuticals: Azurity is the parent/acquirer entity under which the Slayback-branded portfolio has been integrated. Operates the same specialty-pharma business model with overlapping therapeutic-area focus (cardiovascular, CNS, oncology, endocrinology) and shares the 50+ country commercial footprint, making it the closest direct comparability anchor.
- ANI Pharmaceuticals: ANI is a U.S.-based specialty and generic pharmaceutical company with a similar strategy of acquiring and commercializing differentiated, often off-patent or under-promoted prescription products across multiple therapeutic areas — directly comparable to Slayback/Azurity's "overlooked patient" positioning.
- Amneal Pharmaceuticals: Amneal combines specialty, branded, and generics in a diversified portfolio across neurology, endocrinology, and other therapeutic areas. Its branded Specialty segment competes head-to-head with Azurity/Slayback on reformulations and administration-friendly formats for underserved patient populations.
- Mallinckrodt Pharmaceuticals: Mallinckrodt is a specialty pharma focused on brands in CNS, autoimmune, and rare/orphan conditions — overlapping with Slayback/Azurity's CNS, immunology, and oncology-support products and following a similar strategy of revitalizing niche or deprioritized assets.
- Upsher-Smith Laboratories: Upsher-Smith is a privately held U.S. specialty/generic pharma with a portfolio spanning CNS, cardiology, and dermatology. Comparable mid-sized, sponsor-backed company (historically PE-owned) with a similar niche-brand revitalization playbook.
- Padagis: Padagis (formerly Perrigo's generics business) is a specialty generics and OTC company with an extensive branded specialty portfolio. Comparable business model of operating niche, often-deprioritized prescription brands across multiple therapeutic categories.
- Endo International: Endo operates a specialty pharma business (branded sterile injectables, urology, endocrinology) that overlaps with Slayback/Azurity's endocrinology and supportive-care product set, with a similar focus on differentiated formulations and lifecycle management.
Emerging players
- Cumberland Pharmaceuticals: Cumberland is a smaller U.S. specialty pharma focused on hospital and gastroenterology products. Comparable in targeting underserved therapeutic niches with differentiated branded formulations, though materially smaller in scale and geographic reach than Slayback/Azurity.
- Sentynl Therapeutics: Sentynl is a PE-backed (Zydus Group) specialty pharma focused on commercializing niche and rare-disease products — directly comparable "overlooked patient" niche strategy and sponsor profile to Slayback/Azurity.
Broad incumbents
- Bausch Health: Bausch Health's specialty pharma (Salix, Bausch + Lomb Rx) competes in GI, CNS, and ophthalmology categories where Slayback/Azurity has assets (SUPREP, SUTAB, HORIZANT, XATMEP). Larger and broader portfolio, but overlapping therapeutic focus makes it a useful incumbent benchmark.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Slayback Pharma social profiles
Digital presenceSlayback Pharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Slayback Pharma leadership team
Management profileNumber of profiles
Profiles3 records
Slayback Pharma funding detail
Funding detailFunding overview
Funding rounds2 records
Investors2 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Slayback Pharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Slayback Pharma
What does Slayback Pharma do?
Slayback Pharma is a specialty pharmaceutical company that develops, manufactures, and commercializes complex generic and branded prescription medicines across multiple therapeutic areas including cardiovascular, CNS, gastrointestinal, oncology, and endocrinology. The company maintains a diversified portfolio of 50+ medicines spanning 10 dosage forms, with a focus on overlooked patient populations requiring specialized formulations and administration-friendly treatment options.
Is Slayback Pharma a public or private company?
Slayback Pharma is a private company. It is classified as private equity controlled and is currently operating.
When was Slayback Pharma founded?
Slayback Pharma was founded in 2019. It employs 101 to 250 people.
Where is Slayback Pharma based?
Slayback Pharma is headquartered in Princeton, United States, in the North America region.
How does Slayback Pharma make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Slayback Pharma's main competitors?
Direct peers on record are Azurity Pharmaceuticals, ANI Pharmaceuticals, Amneal Pharmaceuticals, Mallinckrodt Pharmaceuticals, Upsher-Smith Laboratories, Padagis and Endo International. Emerging players are Cumberland Pharmaceuticals and Sentynl Therapeutics. Bausch Health is listed as a broad incumbent.
Does Slayback Pharma have an API?
No public API is recorded for Slayback Pharma.
What industry is Slayback Pharma in?
Slayback Pharma's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAB, Specialty Care Pharmaceuticals, with a secondary code of HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.